TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared With Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism
Brief Summary: The purpose of this study is to demonstrate that rivaroxaban is superior to placebo for reducing the risk of the primary composite outcome as defined by objectively confirmed symptomatic lower extremity proximal deep vein thrombosis (DVT), asymptomatic lower extremity proximal DVT, symptomatic lower extremity distal DVT, symptomatic upper extremity DVT, symptomatic non-fatal pulmonary embolism (PE), incidental PE, and venous thromboembolism (VTE)-related death in ambulatory adult participants with various cancer types receiving systemic cancer therapy who are at high risk of developing a VTE.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lenalidomide, Drug: Prednisone, Drug: Melphalan | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): A
B: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for semuloparin) | Intervention Type: DRUG; Name: Semuloparin sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Placebo (for semuloparin); Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bemiparin | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bemiparin; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared With Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism
Brief Summary: The purpose of this study is to demonstrate that rivaroxaban is superior to placebo for reducing the risk of the primary composite outcome as defined by objectively confirmed symptomatic lower extremity proximal deep vein thrombosis (DVT), asymptomatic lower extremity proximal DVT, symptomatic lower extremity distal DVT, symptomatic upper extremity DVT, symptomatic non-fatal pulmonary embolism (PE), incidental PE, and venous thromboembolism (VTE)-related death in ambulatory adult participants with various cancer types receiving systemic cancer therapy who are at high risk of developing a VTE.


Options:
A: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisplatin + docetaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: cisplatin + docetaxel + enoxaparin | Intervention Type: DRUG; Name: cisplatin + docetaxel; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: cisplatin + docetaxel + enoxaparin; Assigned to Arm(s): Arm B
C: Arm Label: Certoparin; Type: EXPERIMENTAL; Interventions: Drug: Certoparin | Arm Label: Unfractionated Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated Heparin | Intervention Type: DRUG; Name: Certoparin; Assigned to Arm(s): Certoparin | Intervention Type: DRUG; Name: Unfractionated Heparin; Assigned to Arm(s): Unfractionated Heparin
D: Arm Label: High TFMP: Enoxaparin; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin | Arm Label: High TFMP: Observation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low TFMP: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): High TFMP: Enoxaparin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: EXpanding Treatment for Existing Neurological Disease (EXTEND)
Brief Summary: The primary goal of the Phase II EXTEND trial is to investigate the effects of open-label hydroxyurea treatment, escalated to maximum tolerated dose, for children with Sickle Cell Anemia and either conditional (170 - 199 cm/sec) or abnormal (≥200 cm/sec) Transcranial Doppler velocities. The primary endpoint will be measured after 18 months of hydroxyurea but treatment will continue until a common study termination date.


Options:
A: Arm Label: Transfusion Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: transfusion therapy | Arm Label: Observation Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: transfusion therapy; Assigned to Arm(s): Transfusion Group
B: Intervention Type: PROCEDURE; Name: blood transfusion; Assigned to Arm(s): N/A
C: Arm Label: Standard Therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Treatment Arm
D: Arm Label: Hydroxyurea Treatment; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea Treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema
Brief Summary: Corticosteroids, whether injected peri- or intra-ocularly, remain indispensable tools of the therapeutic arsenal in treating inflammatory macular edema. However, a few years ago, only triamcinolone acetonide was available to ophthalmologists. This molecule, developed initially for rheumatological or dermatological use, has been increasingly deployed in ophthalmology, while still off-label.

In 2011, the delivery system of dexamethasone from biodegradable and injectable implant into the vitreous cavity obtained the label for inflammatory macular edema. This protocol is therefore designed to compare the efficacy and safety of peri- and intra-ocular injections of corticosteroids in the treatment of inflammatory macular edema.


Options:
A: Arm Label: sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Arm Label: FAI insert; Type: EXPERIMENTAL; Interventions: Drug: FAI insert | Intervention Type: DRUG; Name: FAI insert; Assigned to Arm(s): FAI insert | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): sham injection
B: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A
C: Arm Label: Fluocinolone acetonide 0.59mg; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Fluocinolone acetonide 2.1mg; Type: EXPERIMENTAL; Interventions: Drug: Fluocinolone acetonide 2.1mg | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide 0.59mg | Intervention Type: DRUG; Name: Fluocinolone acetonide 2.1mg; Assigned to Arm(s): Fluocinolone acetonide 2.1mg
D: Arm Label: Reference Drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Tested Drug; Type: EXPERIMENTAL; Interventions: Drug: Triamcinolone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Reference Drug | Intervention Type: DRUG; Name: Triamcinolone; Assigned to Arm(s): Tested Drug

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema
Brief Summary: Corticosteroids, whether injected peri- or intra-ocularly, remain indispensable tools of the therapeutic arsenal in treating inflammatory macular edema. However, a few years ago, only triamcinolone acetonide was available to ophthalmologists. This molecule, developed initially for rheumatological or dermatological use, has been increasingly deployed in ophthalmology, while still off-label.

In 2011, the delivery system of dexamethasone from biodegradable and injectable implant into the vitreous cavity obtained the label for inflammatory macular edema. This protocol is therefore designed to compare the efficacy and safety of peri- and intra-ocular injections of corticosteroids in the treatment of inflammatory macular edema.


Options:
A: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A
B: Arm Label: sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Arm Label: FAI insert; Type: EXPERIMENTAL; Interventions: Drug: FAI insert | Intervention Type: DRUG; Name: FAI insert; Assigned to Arm(s): FAI insert | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): sham injection
C: Arm Label: Reference Drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Tested Drug; Type: EXPERIMENTAL; Interventions: Drug: Triamcinolone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Reference Drug | Intervention Type: DRUG; Name: Triamcinolone; Assigned to Arm(s): Tested Drug
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluocinolone acetonide intraocular implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral corticosteroid with immunosuppressive agents as needed | Intervention Type: DRUG; Name: fluocinolone acetonide intraocular implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: oral corticosteroid with immunosuppressive agents as needed; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized Study on the Skin Functional Parameters to Assess Skin Barrier Improvement After the Use of a Commercially Available Oil Bath Containing 84.75% Soybean Oil Compared to no Bath Additive
Brief Summary: Epidermis that lacks moisture and/or sebum presents as dry skin, which is often characterized by a pattern of fine lines, scaling and itching. In dry skin, the barrier function may be compromised. Skin care practices to decrease the risk of development of dry skin and/or to improve dry skin condition have barely been investigated. Bathing with bath oils has been shown to increase skin hydration, thus helping to stabilize skin barrier function. Therefore, the aim of this study is to investigate the effect of bathing every other day on the skin barrier. Functional parameters, such as TEWL, stratum corneum hydration (SCH) and skin-pH (pH) were measured to characterize skin barrier function.


Options:
A: Arm Label: Balneum oil bath; Type: EXPERIMENTAL; Interventions: Other: Balneum oil bath | Arm Label: standard skin cleanser; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Balneum oil bath; Assigned to Arm(s): Balneum oil bath
B: Arm Label: Observation only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Food intervention; Type: EXPERIMENTAL; Interventions: Other: Food intervention | Arm Label: Skin care; Type: EXPERIMENTAL; Interventions: Other: Skin care | Arm Label: Food intervention and skin care; Type: EXPERIMENTAL; Interventions: Other: Food intervention, Other: Skin care | Intervention Type: OTHER; Name: Food intervention; Assigned to Arm(s): Food intervention, Food intervention and skin care | Intervention Type: OTHER; Name: Skin care; Assigned to Arm(s): Food intervention and skin care, Skin care
C: Arm Label: Daily Emollient; Type: EXPERIMENTAL; Interventions: Other: Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream | Arm Label: Natural Skin; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream; Assigned to Arm(s): Daily Emollient
D: Arm Label: Coconut Oil Application; Type: EXPERIMENTAL; Interventions: Procedure: Coconut Oil Application | Arm Label: No Oil Application; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Coconut Oil Application; Assigned to Arm(s): Coconut Oil Application

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized Study on the Skin Functional Parameters to Assess Skin Barrier Improvement After the Use of a Commercially Available Oil Bath Containing 84.75% Soybean Oil Compared to no Bath Additive
Brief Summary: Epidermis that lacks moisture and/or sebum presents as dry skin, which is often characterized by a pattern of fine lines, scaling and itching. In dry skin, the barrier function may be compromised. Skin care practices to decrease the risk of development of dry skin and/or to improve dry skin condition have barely been investigated. Bathing with bath oils has been shown to increase skin hydration, thus helping to stabilize skin barrier function. Therefore, the aim of this study is to investigate the effect of bathing every other day on the skin barrier. Functional parameters, such as TEWL, stratum corneum hydration (SCH) and skin-pH (pH) were measured to characterize skin barrier function.


Options:
A: Arm Label: Peanut Consumption Group; Type: EXPERIMENTAL; Interventions: Biological: Peanut Consumption Group | Arm Label: Peanut Avoidance Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Peanut Consumption Group; Assigned to Arm(s): Peanut Consumption Group
B: Arm Label: Bathing within 24-48; Type: EXPERIMENTAL; Interventions: Procedure: Bathing | Arm Label: Bathing within 48-72; Type: EXPERIMENTAL; Interventions: Procedure: Bathing | Intervention Type: PROCEDURE; Name: Bathing; Assigned to Arm(s): Bathing within 24-48, Bathing within 48-72
C: Arm Label: Twice daily use treatment with EpiCeram; Type: ACTIVE_COMPARATOR; Interventions: Drug: EpiCeram | Arm Label: Standard skin care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: EpiCeram; Assigned to Arm(s): Twice daily use treatment with EpiCeram
D: Arm Label: Balneum oil bath; Type: EXPERIMENTAL; Interventions: Other: Balneum oil bath | Arm Label: standard skin cleanser; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Balneum oil bath; Assigned to Arm(s): Balneum oil bath

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Chronic Obstructive Pulmonary Disease Transcription Factor and Cytokine Study
Brief Summary: Chronic Obstructive Pulmonary Disease Transcription Factor and Cytokine Study.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Doxycycline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Azithromycin, 250 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Macrolide Antibiotic (Azithromycin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macrolide Antibiotic (Azithromycin); Assigned to Arm(s): Azithromycin, 250 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Moxifloxacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Moxifloxacin | Arm Label: Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Doxycycline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Doxycycline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): Moxifloxacin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): Doxycycline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study of a Multicomponent Nurse Intervention to Reduce the Incidence and Severity of Delirium in Hospitalized Older Adults: MID-Nurse-P
Brief Summary: Objectives: To analyze if a multicomponent nurse-led intervention randomized clinical trial (MID-Nurse Study) is feasible (Pilot study), and can reduce the incidence, duration, and severity of delirium in hospitalized older adults in an AGU.

Design: Parallel-group Double-blind Randomized Clinical Trial (Pilot Study). Setting: AGU "Complejo Hospitalario Universitario from Albacete" (Albacete, Spain).

Participants: 50 patients ≥ 65 years hospitalized in the AGU (21 intervention group, 29 control group).

Interventions: After risk factor analysis, all participants in the intervention group (IG) received a daily multicomponent intervention (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain) by the intervention nurses. The control group (CG) received usual care.

Measurements: Delirium presence was determined daily with the Confusion Assessment Method (CAM), and delirium severity with the Delirium Rating Scale-Revised-98 (DRS). Mortality, days of hospitalization, use of physical restraint measures, and use of drugs for delirium control (neuroleptics and benzodiacepines) were also recorded.


Options:
A: Arm Label: multifaceted prevention program; Type: EXPERIMENTAL; Interventions: Behavioral: Multifaceted prevention program HELP(Hospital Elder Life Program) | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multifaceted prevention program HELP(Hospital Elder Life Program); Assigned to Arm(s): multifaceted prevention program
B: Arm Label: Anesthesiology Control Tower Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Anesthesiology Control Tower Feedback; Type: EXPERIMENTAL; Interventions: Other: Anesthesiology Control Tower Feedback | Intervention Type: OTHER; Name: Anesthesiology Control Tower Feedback; Assigned to Arm(s): Anesthesiology Control Tower Feedback
C: Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Dementia Care Management (DCM); Type: EXPERIMENTAL; Interventions: Behavioral: Dementia Care Management (DCM) | Intervention Type: BEHAVIORAL; Name: Dementia Care Management (DCM); Assigned to Arm(s): Dementia Care Management (DCM)
D: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Multicomponent nurse-led intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Multicomponent nurse-led intervention; Assigned to Arm(s): Intervention Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study of a Multicomponent Nurse Intervention to Reduce the Incidence and Severity of Delirium in Hospitalized Older Adults: MID-Nurse-P
Brief Summary: Objectives: To analyze if a multicomponent nurse-led intervention randomized clinical trial (MID-Nurse Study) is feasible (Pilot study), and can reduce the incidence, duration, and severity of delirium in hospitalized older adults in an AGU.

Design: Parallel-group Double-blind Randomized Clinical Trial (Pilot Study). Setting: AGU "Complejo Hospitalario Universitario from Albacete" (Albacete, Spain).

Participants: 50 patients ≥ 65 years hospitalized in the AGU (21 intervention group, 29 control group).

Interventions: After risk factor analysis, all participants in the intervention group (IG) received a daily multicomponent intervention (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain) by the intervention nurses. The control group (CG) received usual care.

Measurements: Delirium presence was determined daily with the Confusion Assessment Method (CAM), and delirium severity with the Delirium Rating Scale-Revised-98 (DRS). Mortality, days of hospitalization, use of physical restraint measures, and use of drugs for delirium control (neuroleptics and benzodiacepines) were also recorded.


Options:
A: Arm Label: Hydration: Normal Saline (salt water); Type: EXPERIMENTAL; Interventions: Drug: Saline | Arm Label: Placebo: Lower Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Hydration: Normal Saline (salt water) | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Placebo: Lower Saline
B: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Multicomponent nurse-led intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Multicomponent nurse-led intervention; Assigned to Arm(s): Intervention Group
C: Arm Label: Non-Clinically Assisted Hydration arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-Clinically Assisted Hydration arm | Arm Label: Clinically Assisted Hydration arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Clinically Assisted Hydration arm | Intervention Type: OTHER; Name: Non-Clinically Assisted Hydration arm; Assigned to Arm(s): Non-Clinically Assisted Hydration arm | Intervention Type: OTHER; Name: Clinically Assisted Hydration arm; Assigned to Arm(s): Clinically Assisted Hydration arm
D: Intervention Type: PROCEDURE; Name: Orthogeriatric intervention; Assigned to Arm(s): N/A

Answer: B